

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山医药集团股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

This announcement is made by the board (the “**Board**”) of directors (the “**Director(s)**”) of Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

In accordance with the Company’s articles of association, the Company Law of the People’s Republic of China and applicable laws and regulations, the Board proposes to appoint Mr. Li Xiaojun (“**Mr. Li**”) as an executive director of the 9th session of the Board of the Company.

BIOGRAPHICAL DETAILS OF MR. LI

Mr. Li Xiaojun, aged 53, holds a bachelor’s degree and is a member of delegates to the 12th Guangzhou Municipal Congress of the Communist Party of China and the 14th Guangdong Provincial People’s Congress. Mr. Li began his career in July 1995 and has held various positions, including member of the standing committee of the discipline inspection commission, director of the discipline inspection and supervision office and deputy secretary of the discipline inspection commission of Huangpu District of Guangzhou. He also served as the deputy secretary of the party committee and secretary of the discipline inspection commission of the finance bureau of Huangpu District, deputy director of the organization department of the district committee of Huangpu District, deputy secretary and office director of the party working committee of the Wenchong Street in Huangpu District, secretary of the discipline inspection committee of Guangzhou Department Store Enterprise Group Co., Ltd (currently known as Guangzhou Lingnan Business and Travel Investment Group Co., Ltd.) and secretary of the discipline inspection committee of Guangzhou Development Group Co., Ltd.. Additionally, he has held senior roles such as deputy secretary of the party committee, vice chairman and general manager and chairman of Guangzhou Public Transport Group Co., Ltd. Mr. Li has been serving as the secretary of the party committee of the Company since December 2024 and is currently the secretary of the party committee and chairman of Guangzhou Pharmaceutical Holdings Limited. Mr. Li has extensive experience in corporate management, discipline inspection and supervision, financial and taxation management, resources integration, reform and innovation.

TERM OF OFFICE

Upon approval of Mr. Li's appointment by the shareholders of the Company, the Company will enter into a service contract with Mr. Li for a term commencing from the date of approval by the shareholders at the general meeting till the expiry of the tenure of the 9th session of the Board of the Company. Pursuant to the articles of association of the Company, Mr. Li is eligible for re-election upon the expiry of his term of office.

REMUNERATION

Mr. Li's remuneration package for his role as executive Director will not be specified in the service contract. In accordance with the Procedure of the Board of Directors of the Company, the Board or its Nomination and Remuneration Committee shall be responsible for establishing the standards for the evaluation of Directors and conducting such evaluations. When determining or discussing the remuneration of an individual Director, the Board or the Nomination and Remuneration Committee will take into account factors including the remuneration practices of comparable companies, the time commitment and responsibilities required, and the employment conditions of other positions within the Company and its subsidiaries. Mr. Li's remuneration, once determined, will be subject to approval at the Company's general meeting

As at the date of this announcement, save as disclosed, Mr. Li (i) has not held any directorship in any listed public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) has no other major appointment or professional qualification; (iii) has no interest and is not deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong); or (iv) has no relationship with any other Directors, supervisors, senior management or substantial or controlling shareholders of the Company. There is no other matter in relation to the proposed appointment of Mr. Li that needs to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited, nor is there any information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

GENERAL

The proposed appointment of Mr. Li as an executive director of the Company is subject to the approval of the shareholders of the Company by way of ordinary resolution at a general meeting of the Company. A circular containing, among other things, details of the above proposed appointment and a notice of the general meeting will be despatched to the shareholders of the Company as soon as practicable.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 23 December 2024

As at the date of this announcement, the Board comprises Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Wu Changhai and Mr. Li Hong as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.